Secondary Spotlight ‘The most important letters in PE are D-P-I’: Gerald Cooper on the 2024 Secondary Market Landscape Revelation Partners caught up with Gerald Cooper, Head of the North America Secondary Advisory Practice at Campbell Lutyens, to discuss the 2024 fundraising and exit environment, the evolution of the GP-led secondary market, and considerations for GPs […]
VC Secondary Market Partner Perspectives: Mike Boggs
In this fifth (and final) release in a series of interviews with successful figures in the venture capital secondary market, Derek Minno talks with Mike Boggs, a co-founder of Revelation Partners, which manages over $1.5 billion, making the firm the largest dedicated provider targeting healthcare secondaries. This article features Derek’s takeaways from the conversation along […]
Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of RejoynTM, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms
Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Click Therapeutics, Inc., (Click) announce that the U.S. Food and Drug Administration (FDA) has cleared RejoynTM (developed as CT-152), the first prescription digital therapeutic authorized for the treatment of major depressive disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years […]
Hildred Capital Raises $750 Million Continuation Fund
Private-equity firm Hildred Capital Management has closed its first continuation fund to extend its ownership of two consumer-healthcare businesses and inject them with more money for growth.
Nouscom extends Series C round to $82m for cancer vaccine trials
Immuno-oncology company Nouscom has extended a Series C financing round to raise $82m (€75.8m) as it looks to advance its pipeline of personalised and off-the-shelf cancer vaccines. An additional $7.6m was added from Italian venture capital firm Angelini Ventures, joining the round which was first announced in November 2023. The oversubscribed round adds to a Series […]
Mission Therapeutics raises £25.2m to enhance power of mitochondria
Clinical-stage biotech Mission Therapeutics has raised £25.2 million to progress clinical development of its mitophagy clinical candidates.
Secondary Spotlight ‘GP-led Secondaries Should be Another Tool in the Toolkit’: Todd Miller on the 2024 Secondary Market Landscape Revelation Partners caught up with Todd Miller, Global Co-Head of Private Capital Advisory at Jefferies, to discuss the 2024 fundraising and exit environment, the evolution of the GP-led secondary market, and considerations for GPs evaluating GP-led […]
Revelation Partners Expands Team and Promotes Internal Talent
Revelation Partners announced today it is expanding its team as well as promoting internal talent. The firm, which has over $1.5 billion of capital under management and provides liquidity to private healthcare investors, added Courtney Munley as Associate and Paden Rasmussen as Finance Manager, as well as promoted Garrett Brown and Keegan Hasson to Senior Associate, and Colleen Hochberger to Marketing and Operations Associate.
SPR® Therapeutics Announces $85 Million in Additional Funding to Advance Rapid Commercial Expansion of the SPRINT® PNS System
SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or chronic pain, today announced that it has secured $85 million in financing including $25 million in Series D-1 insider equity and a $60 million debt facility. The equity financing was led by Revelation […]
Employee Secondary Surges Amidst the Drought for Liquidity
Historically, private companies have given employees equity incentives as an attractive supplement to cash compensation. However, employees have only been able to convert that paper wealth to cash through acquisition, IPO, or a secondary sale. In the past couple of years, liquidity events have tumbled. After a surge of 311 VC-backed IPOs in 2021, there […]